Therapeutics, Targets and Clinical Translation – Shaping the Next Era of Biologics

PEGS Boston 2027's Oncology stream brings together three tracks charting the fastest-moving areas in cancer biologics — from therapeutic modality choice to novel target discovery to conjugate innovation. Antibodies for Cancer Therapy pits the field's growing set of modalities/platforms side-by-side: costimulatory, conditional activation and logic-gated platforms, and a running comparison across CAR-Ts, TCEs, and TCR-based approaches — including where combination, not competition, is proving to be the winning strategy. Emerging Targets for Oncology & Beyond looks at what comes next — AI-powered target discovery, target multiplexing and pairing strategies, and the wave of new antigens and checkpoint-axis combinations reshaping the pipeline. Driving Clinical Success in Antibody-Drug Conjugates turns to translation, dose optimization, resistance mechanisms, and the dual-payload, multi-target, and novel-conjugate formats pushing ADCs past their first-generation limits. Together, the three tracks give attendees a full view of the field — from discovery through design to clinical execution.

Conferences Include:

May 10-11

Antibody-Based Therapies